These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24859492)

  • 41. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
    Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
    Naber SK; Bruijning-Verhagen PCJL; de Hoog MLA; van Giessen A
    Vaccine; 2020 Apr; 38(17):3387-3396. PubMed ID: 32115297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling.
    Dawa J; Emukule GO; Barasa E; Widdowson MA; Anzala O; van Leeuwen E; Baguelin M; Chaves SS; Eggo RM
    BMC Med; 2020 Aug; 18(1):223. PubMed ID: 32814581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
    Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P
    Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intranasal live attenuated seasonal influenza vaccine: does not challenge current practice.
    Prescrire Int; 2013 Sep; 22(141):201-4. PubMed ID: 24171209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany.
    Falkenhorst G; Harder T; Remschmidt C; Terhardt M; Zepp F; Ledig T; Wicker S; Keller-Stanislawski B; Mertens T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1557-64. PubMed ID: 24170085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-utility analysis of offering a novel remunerated community pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada.
    Pullagura GR; Waite NM; Houle SKD; Violette R; Wong WWL
    J Am Pharm Assoc (2003); 2019; 59(4):489-497.e1. PubMed ID: 30979576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.
    Luce BR; Zangwill KM; Palmer CS; Mendelman PM; Yan L; Wolff MC; Cho I; Marcy SM; Iacuzio D; Belshe RB
    Pediatrics; 2001 Aug; 108(2):E24. PubMed ID: 11483834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
    Van Bellinghen LA; Marijam A; Tannus Branco de Araujo G; Gomez J; Van Vlaenderen I
    Braz J Infect Dis; 2018; 22(1):1-10. PubMed ID: 29352897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Live attenuated influenza vaccine (Fluenz™): a guide to its use in the prevention of seasonal influenza in children in the EU.
    Scott LJ; Carter NJ; Curran MP
    Paediatr Drugs; 2012 Aug; 14(4):271-9. PubMed ID: 22702743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
    Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Edoka I; Kohli-Lynch C; Fraser H; Hofman K; Tempia S; McMorrow M; Ramkrishna W; Lambach P; Hutubessy R; Cohen C
    Vaccine; 2021 Jan; 39(2):412-422. PubMed ID: 33272702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
    de Fougerolles TR; Baïssas T; Perquier G; Vitoux O; Crépey P; Bartelt-Hofer J; Bricout H; Petitjean A
    BMC Public Health; 2024 May; 24(1):1222. PubMed ID: 38702667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany.
    Cai R; Gerlier L; Eichner M; Schwehm M; Rajaram S; Mould-Quevedo J; Lamotte M
    J Med Econ; 2021; 24(1):490-501. PubMed ID: 33761803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.